U.S. Markets closed

Novavax to Present at the 38th Annual J.P. Morgan Healthcare Conference

GAITHERSBURG, Md., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it will present at the 38th Annual J.P. Morgan Healthcare Conference.

Presentation details are as follows:

Date and Time: Thursday, January 16, 11:00 – 11:25 a.m. P.T.
Location:           California West, Westin St. Francis Hotel, San Francisco
Live webcast:    www.novavax.com, “Investors”/“Events”

A replay of the presentation will also be accessible under the “Investors/Events” section www.novavax.com.

About Novavax

Novavax, Inc. (NVAX), is a late-stage biotechnology company that drives improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection which is the second leading cause of death in children under one year of age worldwide. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.


Novavax, Inc.
Erika Trahan

John Woolford

BrandZone/Speak Life Science
Amy Speak